Literature DB >> 18567975

Varenicline-induced mixed mood and psychotic episode in a patient with a past history of depression.

Andres J Pumariega1, Robert Nelson, Larry Rotenberg.   

Abstract

Varenicline is a promising agent with demonstrated efficacy in the promotion of smoking cessation. However, from the time of initial trials, it has been associated with significant psychiatric adverse effects. We describe a case where mixed mood and psychotic disturbance developed in an individual with a history of depression and a family history of bipolar disorder. Based on this case, we hypothesize a possible mechanism of action for these adverse effects and preventive measures that could be undertaken in its effective use.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18567975     DOI: 10.1017/s1092852900016746

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  16 in total

1.  Smoking cessation after brain damage does not lead to increased depression: implications for understanding the psychiatric complications of varenicline.

Authors:  Daniel Tranel; Ashton McNutt; Antoine Bechara
Journal:  Cogn Behav Neurol       Date:  2012-03       Impact factor: 1.600

2.  Smoking outcome by psychiatric history after behavioral and varenicline treatment.

Authors:  Jennifer B McClure; Gary E Swan; Sheryl L Catz; Lisa Jack; Harold Javitz; Tim McAfee; Mona Deprey; Julie Richards; Susan M Zbikowski
Journal:  J Subst Abuse Treat       Date:  2010-04-02

Review 3.  Varenicline for tobacco dependence: panacea or plight?

Authors:  Jill M Williams; Michael B Steinberg; Marc L Steinberg; Kunal K Gandhi; Rajiv Ulpe; Jonathan Foulds
Journal:  Expert Opin Pharmacother       Date:  2011-06-06       Impact factor: 3.889

4.  The smoking cessation drug varenicline improves deficient P20-N40 inhibition in DBA/2 mice.

Authors:  Kristin M Wildeboer-Andrud; Karen E Stevens
Journal:  Pharmacol Biochem Behav       Date:  2011-07-07       Impact factor: 3.533

5.  Late-life Onset Mania After Varenicline Use: A Case Report.

Authors:  Abdullah Akpinar; Gülin Özdamar Ünal; İnci Meltem Atay; Duru Gündoğar; Ramazan Özçankaya
Journal:  Noro Psikiyatr Ars       Date:  2013-12-01       Impact factor: 1.339

6.  Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study.

Authors:  Rachna Kasliwal; Lynda V Wilton; Saad A W Shakir
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

7.  Varenicline augmentation in depressed smokers: an 8-week, open-label study.

Authors:  Noah S Philip; Linda L Carpenter; Audrey R Tyrka; Laura B Whiteley; Lawrence H Price
Journal:  J Clin Psychiatry       Date:  2009-03-24       Impact factor: 4.384

8.  An algorithm for tailoring pharmacotherapy for smoking cessation: results from a Delphi panel of international experts.

Authors:  P Bader; P McDonald; P Selby
Journal:  Tob Control       Date:  2008-10-09       Impact factor: 7.552

9.  Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline.

Authors:  Jennifer B McClure; Gary E Swan; Lisa Jack; Sheryl L Catz; Susan M Zbikowski; Tim A McAfee; Mona Deprey; Julie Richards; Harold Javitz
Journal:  J Gen Intern Med       Date:  2009-02-24       Impact factor: 5.128

Review 10.  Smoking and chronic obstructive pulmonary disease (COPD). Parallel epidemics of the 21 century.

Authors:  Rafael Laniado-Laborín
Journal:  Int J Environ Res Public Health       Date:  2009-01-09       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.